AL002
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
0
Recruiting
0
Completed
2
Sites
129
Countries
12
Endpoints
28
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 28 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 10 of 28 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
4
2
2
2
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| INVOKE-2A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease | AL002 Alzheimer’s disease | Alzheimer's disease | Ph 2 | Completed | 87 | Aug 2024 | 4 | results |
| NCT05744401A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease | AL002 Alzheimer’s disease | Study partner/caregiver required | Ph 2 | Terminated | 54 | Jan 2025 | - | results |
| NCT03635047A Phase I Study for Safety and Tolerability of AL002. | AL002 Alzheimer’s disease | Alzheimer's disease | Ph 1 | Completed | 6 | Aug 2020 | 1 |
Showing 1-3 of 3 trials